After another loss in the US Court of Appeals, Teva will seek a certiorari review by the US Supreme Court of its long-running inhaler patent case against Amneal.
Supreme Court May Be Next After Federal Circuit Refuses To Rehear Teva Inhaler Patents Case
Teva was forced to delist its ProAir HFA inhaler patents from the FDA’s Orange Book by mid-March after the Federal Circuit denied its petition for en banc rehearing. Will the Supreme Court listen?
